Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 98

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 98
---
under, including Regulation M, which may limit the timing of purchases and sales of the Depositary Shares by the
selling shareholders or any other person. We will make copies of this prospectus available to the selling shareholders and have informed
them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with
Rule 172 under the Securities Act).

| 50 |

<div align='center'>LEGAL MATTERS</div>

Brown Rudnick LLP, London, United Kingdom
has passed upon certain legal matters regarding the securities offered hereby.

<div align='center'>EXPERTS</div>

The financial statements as of December
31, 2024, and for the year then ended, incorporated by reference into this prospectus and in the registration statement have been so incorporated in reliance on a report PKF Littlejohn LLP, an independent registered accounting firm, given on authority of said firm as experts in auditing and accounting. The report on the financial statements for the year ended December 31, 2024 contains an explanatory paragraph regarding our ability to continue as a going concern.

PKF Littlejohn LLP, London, United
Kingdom, is a member of the Institute of Chartered Accountants in England and Wales.

The financial statements of Biodexa
Pharmaceuticals PLC as of December 31, 2023, and for each of the three years in the period then ended, incorporated by reference in this
prospectus and in the registration statement have been so incorporated in reliance on a report of Forvis Mazars LLP (then-named Mazars
LLP), an independent registered public accounting firm, given on authority of said firm as experts in auditing and accounting. The report on the financial statements for the year ended December 31, 2023, contains an explanatory paragraph in Note 2 regarding our ability to continue as a going concern.

Forvis Mazars LLP, London, United Kingdom,
is a member of the Institute of Chartered Accountants in England and Wales.

<div align='center'>WHERE YOU CAN FIND MORE INFORMATION</div>

We have filed with the SEC a registration
statement on Form F-1, including amendments and relevant exhibits and schedules, under the Securities Act covering the Ordinary Shares
represented by Depositary Shares to be sold in this offering. This prospectus, which constitutes a part of the registration statement,
summarizes material provisions of contracts and other documents that we refer to in the prospectus. Since this prospect